Nektar Therapeutics (NKTR - Get Report) is expected to report a loss of 55 cents a share on sales of $44.8 million after the market closes Feb. 28, based on a FactSet survey of 11 analysts.

In the same period a year ago the company posted a loss of 21 cents a share on sales of $95.5 million. The stock has risen 8.1% since the company last reported earnings on Nov. 7. Quarterly estimates have fallen 1.2 cent a share in the past month. 

Jim Cramer and the AAP team are watching the pharmaceuticals sector. To find out more about what stocks they like in the industry click here now to get more from Action Alerts PLUS.